GlobeNewswire 28/07/2025 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
GlobeNewswire 24/07/2025 argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 202...
GlobeNewswire 23/07/2025 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
GlobeNewswire 18/07/2025 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
GlobeNewswire 14/07/2025 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
GlobeNewswire 10/07/2025 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
GlobeNewswire 06/07/2025 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
GlobeNewswire 01/07/2025 Unnatural Products Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Pept...
GlobeNewswire 30/06/2025 argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
GlobeNewswire 20/06/2025 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflamma...
GlobeNewswire 11/06/2025 argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept R...
GlobeNewswire 03/06/2025 argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire 28/05/2025 argenx Announces Results of Annual General Meeting of Shareholders
GlobeNewswire 15/05/2025 New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeli...
GlobeNewswire 08/05/2025 argenx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire 07/05/2025 American Kidney Fund’s Kidney Action Summit Brings AKF Ambassadors to Capitol Hill to Urge Support o...
GlobeNewswire 06/05/2025 argenx to Present at BofA Securities 2025 Health Care Conference
GlobeNewswire 01/05/2025 argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
GlobeNewswire 28/04/2025 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Ch...
GlobeNewswire 24/04/2025 American Kidney Fund Announces 2025 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire 11/04/2025 argenx Announces Annual General Meeting of Shareholders on May 27, 2025
GlobeNewswire 10/04/2025 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized...
GlobeNewswire 08/04/2025 argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Q...
GlobeNewswire 07/03/2025 argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the A...
GlobeNewswire 27/02/2025 argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update